Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip D Home

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Cardiovascular Diabetology|April 26, 2008
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)Michel Komajda, Paula Curtis, Markolf Hanefeld, et al.
Diabetes Care|March 21, 2025
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 DiabetesGeremia B Bolli, Philip D Home, Francesca Porcellati, et al.
Diabetes, Obesity & Metabolism|July 7, 2020
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparisonPhilip D Home, Vanita R Aroda, Lawrence Blonde, et al.
The New England Journal of Medicine|June 7, 2007
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysisPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
The Journal of Clinical Endocrinology and Metabolism|November 10, 2009
Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapyS K Abdul Shakoor, Ali Aldibbiat, Lorna E Ingoe, et al.
Diabetes Care|August 23, 2014
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forumWilliam T Cefalu, John B Buse, Stefano Del Prato, et al.
European Heart Journal|February 2, 2010
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialMichel Komajda, John J V McMurray, Henning Beck-Nielsen, et al.
Diabetes Research and Clinical Practice|April 1, 2015
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continentsPhilip D Home, Marie-Paule Dain, Nick Freemantle, et al.
Lancet (London, England)|June 9, 2009
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Diabetes Technology & Therapeutics|February 4, 2016
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 DiabetesMatthew C Riddle, Geremia B Bolli, Philip D Home, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Cardiovascular Diabetology|April 26, 2008
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)Michel Komajda, Paula Curtis, Markolf Hanefeld, et al.
Diabetes Care|March 21, 2025
The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 DiabetesGeremia B Bolli, Philip D Home, Francesca Porcellati, et al.
Diabetes, Obesity & Metabolism|July 7, 2020
Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparisonPhilip D Home, Vanita R Aroda, Lawrence Blonde, et al.
The New England Journal of Medicine|June 7, 2007
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysisPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
The Journal of Clinical Endocrinology and Metabolism|November 10, 2009
Endothelial progenitor cells in subclinical hypothyroidism: the effect of thyroid hormone replacement therapyS K Abdul Shakoor, Ali Aldibbiat, Lorna E Ingoe, et al.
Diabetes Care|August 23, 2014
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forumWilliam T Cefalu, John B Buse, Stefano Del Prato, et al.
European Heart Journal|February 2, 2010
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trialMichel Komajda, John J V McMurray, Henning Beck-Nielsen, et al.
Diabetes Research and Clinical Practice|April 1, 2015
Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continentsPhilip D Home, Marie-Paule Dain, Nick Freemantle, et al.
Lancet (London, England)|June 9, 2009
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Diabetes Technology & Therapeutics|February 4, 2016
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 DiabetesMatthew C Riddle, Geremia B Bolli, Philip D Home, et al.
Pageof 7